Literature DB >> 26210998

Successful treatment of macrophage activation syndrome due to systemic onset juvenile idiopathic arthritis with antithymocyte globulin.

Kubra Ozturk1, Zelal Ekinci2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26210998     DOI: 10.1007/s00296-015-3321-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  5 in total

Review 1.  Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin.

Authors:  Andreea Coca; Kemp W Bundy; Bethany Marston; Jennifer Huggins; R John Looney
Journal:  Clin Immunol       Date:  2009-03-17       Impact factor: 3.969

Review 2.  Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment.

Authors:  A Ravelli; A A Grom; E M Behrens; R Q Cron
Journal:  Genes Immun       Date:  2012-03-15       Impact factor: 2.676

3.  2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.

Authors:  Sarah Ringold; Pamela F Weiss; Timothy Beukelman; Esi Morgan DeWitt; Norman T Ilowite; Yukiko Kimura; Ronald M Laxer; Daniel J Lovell; Peter A Nigrovic; Angela Byun Robinson; Richard K Vehe
Journal:  Arthritis Rheum       Date:  2013-10

4.  Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients.

Authors:  Nizar Mahlaoui; Marie Ouachée-Chardin; Geneviève de Saint Basile; Bénédicte Neven; Capucine Picard; Stéphane Blanche; Alain Fischer
Journal:  Pediatrics       Date:  2007-08-14       Impact factor: 7.124

Review 5.  Macrophage activation syndrome and cytokine-directed therapies.

Authors:  Grant S Schulert; Alexei A Grom
Journal:  Best Pract Res Clin Rheumatol       Date:  2014-04       Impact factor: 4.098

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.